Business

Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

RICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Heli...

articleHelix Biopharma Corp.September 20, 20213/company/helix-biopharma-corp/news/helix-biopharma-corp-announces-appointment-of-interim-chief-executive-officer
Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

About this update from Helix Biopharma Corp.

[{"type":"text","content":"Helix BioPharma Corp. Announces Appointment of Interim Chief Executive OfficerRICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) (\"Helix\" or the \"Company\"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chairman of the Board, Prof. Dr. Slawomir Majewski, will immediately assume the role of Interim CEO while the Company continues to identify and evaluate candidates.About Helix BioPharma Corp.Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the Toronto Stock Exchange under the symbol \"HBP.\"For more information, please contact:Helix BioPharma Corp.9120 Leslie Street, Suite 205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300 x 233Frank Michalargias, Chief Financial [email protected] RelationsAlpha Bronze, LLCMr. Pascal NigenPhone: + 1 (917) [email protected] Statements and Risks and UncertaintiesThis news release contains forward-looking statements and information (collectively, \"forward-looking statements\") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and other information in future periods. Forward-looking statements can further be identified by the use of forward-looking terminology such as \"ongoing\", \"estimates\", \"expects\", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions \"will\", \"may\", \"could\", or \"should\" occur or be achieved, or comparable terminology referring to future events or results.Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Alt...

More updates from Helix Biopharma Corp.